| Literature DB >> 31075743 |
Hamed Nosrati1, Fatemeh Abhari2, Jalil Charmi3, Soodabeh Davaran4, Hossein Danafar5.
Abstract
In this project methotrexate (MTX) conjugated albumin based nanoparticles (MTX-BSA) loaded with curcumin (CUR) drug (CUR-MTX-BSA) for simultaneous delivery of multi-chemotherapeutic drugs and combination cancer therapy were designed. Co-delivery is a new strategy which minimize the amount of each drug, reduce of side effects and also to achieve the synergistic effect for cancer therapies. The MTX was conjugated to albumin via covalent bond. Next, this synthesized prodrug loaded with CUR. Afterward, the formulations were evaluated for physical and chemical properties by DLS, TEM, FTIR, UV/Vis, DSC analysis, in vitro cytotoxicity and in vivo biocompatibility studies. Furthermore, the drug loading and release study were evaluated. Proteinase K enzyme was used to break amid bond between MTX and BSA and also amidic bonds in BSA structure. Administration of up to 2000 mg/kg of BSA to healthy animals was non-toxic and all treated mice were still alive after 24 h. The result of this study proved that CUR-MTX-BSA can be used as a proficient vehicle for effective co-delivery of CUR and MTX in the treatment of cancer.Entities:
Keywords: Albumin; BSA; Co-delivery; Curcumin; Methotrexate; Simultaneous delivery
Mesh:
Substances:
Year: 2019 PMID: 31075743 DOI: 10.1016/j.bioorg.2019.102959
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275